Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive neoplasm derived from plasmacytoid dendritic cells. 1 In 2008, BPDCN was classified by the World Health Organization (WHO) as a distinct entity in the group of "acute myeloid leukemia (AML) and related precursor neoplasms". 2 Although elderly subjects are principally affected, BPDCN can also arise in young adults and children. 3, 4 Approximately 90% of patients exhibit cutaneous lesions at diagnosis, which upon microscopic analysis appear as a dermal infiltrate of immature blastic cells with features of plasmacytoid dendritic cells. 5, 6 Malignant cells isolated from skin, lymph nodes, bone marrow, spleen and/or other tissues usually express the following markers: interleukin-3 receptor alpha (IL-3Ra or CD123), BDCA2 (CD303), BDCA4 (CD304), TCL1 and ILT7. [7] [8] [9] Currently, there is no consensus regarding the optimal treatment modality for BPDCN. Several treatments, including multi-agent chemotherapy regimens, symptomatic approaches (e.g. local radiation 10 ), and intensive chemotherapy with allogeneic hematopoietic cell transplantation, [11] [12] [13] are generally used to treat patients. Although chemotherapy regimens used to treat patients with acute leukemia or lymphoma are often effective at inducing an initial response, the duration of response is typically brief and recurrent disease is generally resistant to chemotherapy. BPDCN patients generally succumb to cytopenias due to tumor infiltration of the bone marrow; the median overall survival has been reported to range from 9 to 32 months irrespectively of the initial presentation of the disease. [14] [15] [16] While longer overall survival has been reported with allogeneic hematopoietic cell transplantation, especially in younger patients, 4, 11, 13, 16, 17 many relapses have been observed after such transplants. 13 The a-subunit of the human IL-3 receptor is a type I transmembrane glycoprotein belonging to the cytokine receptor superfamily. 18, 19 Interleukin-3 (IL-3) the IL-3 receptor is a heterodimer associating an a chain (CD123) and a β chain (CD131). This chain is shared by IL-3, IL-5, and granulocytemacrophage colony-stimulating factor receptors. SL-401, a novel biologic targeted therapy directed against the IL-3R, is comprised of human recombinant IL-3 joined by an acid- Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor a chain (IL3-Ra or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dosedependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P<0.001). These findings indicate that blastic plasmacytoid dendritic cell neoplasm cells are highly sensitive to SL-401, and support further evaluation of SL-401 in patients suffering from blastic plasmacytoid dendritic cell neoplasm.
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Given the ubiquitous and high expression of IL-3R by BPDCN and the lack of therapies available to treat BPDCN, SL-401 is a potential therapeutic for BPDCN. The present study evaluated the cytotoxicity of SL-401 against patient-derived BPDCN cell lines (CAL-1 and GEN2.2) and primary BPDCN cells isolated directly from 12 patients. The investigations were performed in vitro, as well as in vivo in a murine model of BPDCN. The aim of the study was to provide further support for the use of SL-401 in patients suffering from BPDCN.
Methods

Patients' cells and cell lines
Peripheral blood or bone marrow cells were obtained for diagnostic purposes from 12 BPDCN patients (Table 1) 
Drug and culture
The SL-401 drug (Stemline Therapeutics, New York, NY, USA) was stored at -80°C and tested at eight concentrations ranging from 365 pM to 0.08 fM (21 ng/mL to 0.4 ng/mL) in order to cover 
Cytotoxicity evaluation by flow cytometry
Flow cytometry was performed using a CANTO II cytometer (BD Biosciences, San Jose, CA, USA) and DIVA 6.2 software (BD Biosciences). The cytotoxic effects of SL-401 and the various drugs were evaluated using annexin-V and 7-amino actinomycin D (AV/7AAD) and a panel of different monoclonal antibodies to gate the blastic population described in the Online Supplementary Appendix. In the mouse model, anti-mouse and anti-human CD45 plus anti-human CD123, CD4, CD56, CD304 were used to identify BPDCN human cells (Online Supplementary Appendix). A defined number of calibrated 3-mm latex beads (Flowcount beads, Beckman Coulter) was added to each sample to obtain the absolute number of circulating BPDCN cells in mice, as previously described.
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Cytotoxicity evaluation by the MTT assay
The percentage of viable cells obtained after incubation with or without SL-401 was assessed using the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma Aldrich, Saint Quentin Fallavier, France). Details of the culture and following analysis are provided in the Online Supplementary Appendix.
Mice
NOD-SCID IL2Rγc-deficient (NSG) mice were irradiated (2 Gy) and inoculated intravenously 24 h later with 1x10 6 GEN2.2 cells and treated intraperitoneally 8 days later with five daily injections of SL-401 (2 mg/mouse/injection, total experimental dose 100 mg/kg) or with phosphate-buffered saline (PBS) only. Mice were monitored weekly by blood cell counts and flow cytometry (Online Supplementary Appendix).
Statistical analysis
Statistical analyses were performed using Statel software 2.6 (Adscience, Paris, France) (Online Supplementary Appendix).
Results
SL-401 is cytotoxic against blastic plasmacytoid dendritic cell neoplasm cell lines and primary cells
The viability of the two CD123 pos BPDCN cell lines, GEN2.2 and CAL-1, decreased from 62 ± 6% (range, 44-96) to 5 ± 2% (range, 0-17) after treatment with SL-401 at the experimental dose of 365 pM (21 ng/mL) for 18 h (n=9, Figure 1A ). Moreover the viability of these two BPDCN cell lines decreased in a dose-dependent manner ( Figure  1B) . Similarly, after treatment with SL-401 at the experimental dose of 365 pM (21 ng/mL), the viability of 12 samples of freshly isolated BPDCN primary cells decreased significantly from 50 ± 4% (range, 31-71) to 10 ± 1% (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . As expected, the CD123 neg (Daudi) cells were not sensitive to treatment with SL-401 concentrations as high as 365 pM for 18 h [viability was unchanged from 65% (range, 88-41) to 61% (range, 83-41) in cells untreated or treated with SL-401, respectively, n=3; Figure 1A ,B].
SL-401 is cytotoxic against blastic plasmacytoid dendritic cell neoplasm primary cells in a concentration-dependent manner
The viability of primary malignant cells obtained from 12 BPDCN patients treated with SL-401 for 18 or 48 h decreased in a concentration-dependent manner, as assessed by flow cytometry and MTT ( Figure 1C,D) . As expected, CD123
neg Daudi cells were resistant to SL-401 treatment ( Figure 1C,D) . For patient #10, primary BPDCN cells were obtained at both the time of diagnosis and disease relapse following treatment with chemotherapy [including CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone), methotrexate, and Lasparaginase]. Interestingly, BPDCN cells obtained at disease recurrence were slightly more sensitive to SL-401 than cells obtained at diagnosis (IC 50 , 6 fM versus 79 fM, respectively; P=0.049; Figure 1E ). Thus, relapsing cells were still sensitive to SL-401 in a concentration-dependent manner, indicating that BPDCN cells retain their sensitivity to SL-401 following treatment with various cytotoxic agents, thereby suggesting a lack of cross-resistance.
SL-401 is more efficient than other tested chemotherapeutic drugs − except idarubicin − at killing blastic plasmacytoid dendritic cell neoplasm cells
In order to appreciate the cytotoxic effect of SL-401 better, we also assessed the effects of other chemotherapeutic drugs. Primary malignant cells obtained from three BPDCN patients (#7, #9 and #11) were significantly more sensitive to SL-401 than to a wide variety of cytotoxic agents commonly used for the treatment of hematologic malignancies, including cytosine arabinoside, cyclophosphamide, vincristine, dexamethasone, methotrexate, Erwinia L-asparaginase, and asparaginase (Figure 2 ; P<0.05 for all agents). Only idarubicin was found to be more efficient than SL-401 (viability <1%, n=5; Figure 2 ).
Blastic plasmacytoid dendritic cell neoplasm primary cells are more sensitive to SL-401 than acute myeloid or lymphoblastic leukemia primary cells in vitro
We next assessed the viability after SL-401 treatment of primary malignant cells isolated from three previously untreated patients suffering from acute lymphoblastic leukemia and six untreated patients suffering from AML. We compared these results to those achieved following SL-401 treatment of primary BPDCN cells. Figure 3 ].
CD123 expression correlates with SL-401 cytotoxicity in vitro
We next compared the relative expression levels of IL3Ra (CD123) and β (CD131) chains in primary malignant 
Treatment with SL-401 significantly increases the overall survival of NSG mice inoculated with blastic plasmacytoid dendritic cell neoplasm cells
Irradiated NGS mice were inoculated with the GEN2.2 cell line (1x10 6 cells per mouse) through the tail vein. Eight days after inoculation, mice were treated with a daily intra-peritoneal injection of SL-401 (2 mg/day) for 5 days or with PBS as controls (n=8 mice in 3 independent experiments). In PBS-treated control mice, the mean overall survival was 17±1 days. Treatment with five daily injections of SL-401 significantly increased the overall survival of mice compared to that of control mice (58 ± 2 days; P<0.001; Figure 4A Figure 4C ). This suggests that one course of SL-401 (2 µg/day for 5 days) is not sufficient to kill all of the BPDCN cells, rather that CD123 neg BDPCN cells emerge in response to SL-401. In PBS-treated control mice, the number of BPDCN cells progressively increased until death, whereas treatment for 5 days with SL-401 successfully reduced circulating BPDCN cells to undetectable levels for 15±3 days after treatment ( Figure 4D ). We monitored hemoglobin and platelet counts in mice to assess leukemic cell bone marrow involvement. In PBS-treated control mice inoculated with BPDCN, hemoglobin and platelet counts progressively decreased until death. In contrast, in treated mice, these hematologic parameters reached the levels observed in irradiated control mice that were not inocula ted 
Expression of IL-3Ra and β chains (CD123 and CD131) −measured by flow cytometry− in BPDCN cells from patients (# 1-4, 7, 9 and 10), or in different AML, ALL and cell lines (results represent the mean of 2 determinations). Percentage of viability after culture with SL-401 (experimental dose 365 pM= 21 ng/mL) in one experiment (▪), mean±SEM of two ( * ), three (°) or
100 (2)with BPDCN cells and not treated ( Figure 4E ). Regression of cytopenia under treatment indicates an absence, or at least, a lower level of bone marrow involvement by BPDCN cells in SL-401 treated mice. Overall, SL-401 is effective in controlling BPDCN cells in vivo.
Discussion
SL-401 is a biologic agent corresponding to IL-3 genetically fused to truncated DT via a cleavable linker. This agent induces cytotoxicity by inhibiting ribosomal function, and thereby, inhibiting protein synthesis, a mechanism that is distinct from all other anticancer therapeutics. 20 SL-401 has been demonstrated to induce a profound cytotoxicity at picomolar and subpicomolar concentrations in AML cell lines, 26 as well as in a model of human AML inoculated into immunocompromised mice. 27 Moreover, SL-401 is cytotoxic in vivo, in patients with advanced AML and myelosdysplastic syndrome, 23 suggesting that SL-401 targets leukemic stem cells, as well as more mature tumor cells. In contrast, SL-401 is not cytotoxic to normal hematopoietic progenitor cells, 28 which has translated into a paucity of myelosuppression in clinical trials to date. 23, [28] [29] [30] [31] The present study was performed to evaluate and quantify the effects of SL-401 on various preclinical models of BPDCN, a malignancy that ubiquitously expresses high levels of the IL-3Ra chain, which is the target of SL-401.
The 32 In addition, SL-401 produced a robust antitumor effect in an in vivo xenograft model using human BPDCN cells. This also indicates a potential good therapeutic index, as well as systemic activity, since mice survived more than 40 days after SL-401 treatment. The high sensitivity of BPDCN to SL-401 and the potential good therapeutic index of this agent likely reflect the high specificity of the IL-3 ligand component of SL-401 for CD123, in addition to the mechanism of action and potency for its DT payload. Since the IL-3 component of SL-401 is bound via an amino acid linker to a DT for which the receptor binding site is truncated, free DT is essentially inert from a toxicity standpoint. DT can only be delivered intracellularly following the binding of SL-401 to the IL-3R via IL-3 and internalization. Since IL-3Ra expression is limited to only a few normal tissues (plasmacytoid dendritic cells and basophils) and, in contrast, the receptor is overexpressed by BPDCN cells, SL-401 can potentially confer high therapeutic indexes for patients. Additionally, SL-401 is not a substrate for p-glycoprotein and other efflux F. Angelot-Delettre et al. 228 haematologica | 2015; 100(2) pumps, and thus, cannot be excluded from the blastic cells. Moreover, its cytotoxic mechanism, binding to ADPribosylated elongation factor 2, thereby uncoupling protein synthesis blockade, does not overlap with other agents currently used. 22 IL-3 has also been shown to be a critical survival factor for plasmacytoid dendritic cells. 33 Thus, interference of this pathway by SL-401 may explain the high sensitivity of BPDCN compared with the sensitivity of other myeloid and lymphoid leukemic cells.
There is still no consensus on the best therapeutic approach for BPDCN, 3, [12] [13] [14] [15] [34] [35] [36] [37] [38] and, overall, BPDCN remains a chemotherapy-resistant disease and may also resist the graft-versus-leukemia effect, since 32% of patients relapse after allogeneic hematopoietic cell transplantation according to a recent study. 13 Thus, targeted or immune-based therapies are alternative strategies to treat this aggressive leukemia. [39] [40] [41] Here, we propose that SL-401 is an efficient target-based therapy available for clinical trials and has already been shown to have favorable effects in patients with refractory or relapsed AML or myelodysplastic syndrome, although expression of CD123 is lower on myeloid blasts than on BPDCN cells. 23 We recently published data from a phase I/II clinical study involving 11 BPDCN patients. These data showed that a single cycle of SL-401 induced major responses in 78% of the patients. 24 The way to use SL-401 in BPDCN patients must, howe ver, be discussed in the light of data from literature obtained in such patients. SL-401 can be used to consolidate the effects of first-line chemotherapy, reducing the number of relapses, which always occur after chemothe rapy treatment. The combination of SL-401 with chemotherapy should make it possible to reduce chemotherapy doses, and consequently, their adverse effects, which are significant in elderly patients with comorbidities (i.e., most of the patients with BPDCN). We showed here that idarubicin, at the dose we tested, induces a relevant level of cytotoxic activity in vitro whereas cytosine arabinoside does not. This confirms recent data showing that the BPDCN cell line CAL-1 is resistant to cytosine arabinoside. 41 Intrathecal injection of SL-401 could also be of interest since there are frequently patients with central nervous system relapse 42 and the molecular weight of SL-401 (57 KDa) predicts no diffusion across the blood-brain barrier. For patients who undergo allogeneic hematopoietic cell transplantation, SL-401 treatment can be used before allografting to minimize the level of minimal residual disease, which is the most important prognostic factor in a recent study on allografted BPDCN patients, 13 or as a consolidation treatment after allogeneic hematopoietic cell transplantation. 13 In support of this latter use, we observed that, in vitro, the blastic cells from a relapsing BPDCN patient were still sensitive to SL-401-mediated death. Moreover, the IL-3Ra chain (CD123) was still expressed on the surface at relapse (CD123 MFI at diagnosis: 5509 versus 5137 at relapse, patient #10). In the mouse model after one course of SL-401, all the BPDCN cells at relapse also expressed CD123. This supports the hypothesis that patients suffering from BPDCN can be treated with SL-401 as first-line or second-line therapy and, maybe, even with several courses of SL-401. Overall, immune-based therapy using SL-401 appears to be an appropriate way to treat BPDCN patients. New approaches based on immunomodulators 41 or demethylating agents 40 must be further evaluated and compared − or associated − with SL-401.
In conclusion, we demonstrate that clinical grade SL-401, which specifically targets IL-3R, efficiently kills primary BPDCN cells in culture and significantly improves the overall survival of mice inoculated with BPDCN receiving a single cycle of SL-401. This provides a strong rationale for the use of SL-401 in the treatment of patients suffering from BPDCN. As BPDCN is a rare subtype of leukemia, an international clinical trial using SL-401 should now be conducted to validate these results prospectively.
